undamentalytics Newsletter
Sign in

Xenetic Biosciences, Inc. income statement

In fiscal 2025, Xenetic Biosciences, Inc. reported revenue of $3.0m, up 19.0% on the year before, operating income of −$2.8m (a -95.2% margin) and net income of −$2.7m, or −$1.58 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue010038000123333
Cost of revenue000————————————
Gross profit010————————————
Research and development2363444352353333
General and administrative477677453444333
Operating income−6−9−13−10−47−4−7−13−14−6−7−5−4−3−3
Interest expense000010—————————
Net interest income—————−000000000—
Income before tax−6−9−14————————————
Income tax—0000000−3000000
Net income−6−9−14−13−54−4−7−13−11−6−7−4−4−3−2
Diluted EPS−$1.50−$2.10−$0.03−$88.80−$1.96−$0.10−$24.15−$63.30−$1.70−$0.55−$4.61−$2.71−$2.57−$1.58−$1.19
Diluted shares (average)4m4m5m——————1m1m2m2m2m2m
EBITDA−6−9−13−10−47−4−7−13−14−6−7————

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: UPB vs XBIOALGS vs XBIODYAI vs XBIO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Xenetic Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Xenetic Biosciences, Inc.